Evidence map›Paper›PMID 29137428›Full record

ArticleOncotarget2017

Milan S Geybels, Min Fang, Jonathan L Wright, Xiaoyu Qu, Marina Bibikova, Brandy Klotzle, Jian-Bing Fan, Ziding Feng, Elaine A Ostrander, Peter S Nelson and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  2. Article
  3. Review
  4. Exploring therapeutic applications ofFrontiers in oncology · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Milan S GeybelsDepartment of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Min FangDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Jonathan L WrightDivision of Public Health Sciences, Fred Hutchison Cancer Research Center, Seattle, Washington, USA.
Xiaoyu QuDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Marina BibikovaDepartment of Oncology, Illumina, Inc., San Diego, California, USA.
Brandy KlotzleDepartment of Oncology, Illumina, Inc., San Diego, California, USA.
Jian-Bing FanDepartment of Oncology, Illumina, Inc., San Diego, California, USA.
Ziding FengDepartment of Biostatistics, MD Anderson Cancer Center, Houston, Texas, USA.
Elaine A OstranderCancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
Peter S NelsonDivision of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchison Cancer Research Center, Seattle, Washington, USA.
Fred Hutch Cancer Center · USIllumina (United States) · USUniversity of Washington · USCancer Genetics (United States) · USThe University of Texas MD Anderson Cancer Center · US

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Finding Genes for Human Prostate CancerZIAHG200325 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI OSTRANDER, ELAINE · 2009 to 2021
$17.7M
NSAIDS and Other Medications in Prostate Cancer EtiologyR01CA092579 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2001 to 2005
$3.2M
Aggressive Prostate Cancer: Linking Epigenomics and Genetics for PreventionK05CA175147 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2014 to 2018
$445k
PROSTATE CANCER IN RELATION TO VASECTOMYR01CA056678 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1993 to 1997
–
NCI NIH HHS K05 CA175147NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA056678NCI NIH HHS R01 CA092579
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) with loss of the tumor suppressor gene

methodsThe cohort included patients with clinically localized PCa. Samples taken from the primary tumor were used to determine

resultsThe study included 471 patients with data on

conclusionLoss of

Indexed as

epigeneticsphosphatase with tensin homologyprostate tumor methylationrecurrence and prognosis

Identifiers

PMID29137428
PMCPMC5663600
OpenAlexW2754472919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.